rupiya.io
⠋Loading...
0%
❯ Pulling quarterly results...
Piramal Pharma Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Piramal Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | ₹6,315 Cr | ₹6,559 Cr | ₹7,082 Cr | ||
| Expenses | ₹4,887 Cr | ₹5,609 Cr | ₹6,453 Cr | ||
| Operating Profit | ₹1,428 Cr | ₹950 Cr | ₹629 Cr | ||
| OPM % | 23.0% | 14.0% | 9.0% | ||
| Other Income | ₹230 Cr | ₹319 Cr | ₹272 Cr | ||
| Depreciation | ₹545 Cr | ₹586 Cr | ₹677 Cr | ||
| Interest | ₹163 Cr | ₹198 Cr | ₹344 Cr | ||
| Profit Before Tax | ₹949 Cr | ₹485 Cr | ₹-120 Cr | ||
| Tax | ₹949 Cr | ₹485 Cr | ₹-120 Cr | ||
| Net Profit | ₹835 Cr | ₹376 Cr | ₹-186 Cr | ||
| EPS (₹) | 0.0 | 0.0 | -1.4 | ||
| Dividend Payout % | 0% | 18% | 0% |
Register free to see 2 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹2,164 Cr | ₹1,749 Cr | ₹1,911 Cr | ₹1,959 Cr | ||||||||
| Expenses | ₹1,812 Cr | ₹1,617 Cr | ₹1,646 Cr | ₹1,690 Cr | ||||||||
| Operating Profit | ₹351 Cr | ₹132 Cr | ₹266 Cr | ₹268 Cr | ||||||||
| OPM % | 16.2% | 7.6% | 13.9% | 13.7% | ||||||||
| Depreciation | ₹184 Cr | ₹174 Cr | ₹185 Cr | ₹186 Cr | ||||||||
| Interest | ₹104 Cr | ₹119 Cr | ₹110 Cr | ₹106 Cr | ||||||||
| Net Profit | ₹50 Cr | ₹-99 Cr | ₹5 Cr | ₹10 Cr | ||||||||
| EPS (₹) | 0.4 | -0.8 | 0.0 | 0.1 |
Register free to see 8 more quarters.
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹995 Cr | ₹1,186 Cr | ₹1,193 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹4,610 Cr | ₹5,511 Cr | ₹5,580 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹3,025 Cr | ₹4,128 Cr | ₹5,637 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹2,047 Cr | ₹1,781 Cr | ₹1,893 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹10,677 Cr | ₹12,605 Cr | ₹14,303 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹6,105 Cr | ₹6,879 Cr | ₹7,469 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹123 Cr | ₹267 Cr | ₹639 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹3,822 Cr | ₹4,286 Cr | ₹4,777 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹10,677 Cr | ₹12,605 Cr | ₹14,303 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 2 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2022 | ₹598 Cr | ₹-4,464 Cr | ₹3,977 Cr | — |
| Mar 2023 | ₹766 Cr | ₹-1,737 Cr | ₹794 Cr | — |
| Mar 2024 | ₹484 Cr | ₹-1,334 Cr | ₹818 Cr | — |
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 2 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.